标准的抗癌化疗药物常常会产生显著的副作用，并且最终会由于耐药机制的出现而失去疗效。因此，恶性肿瘤患者的生活质量很差，寿命短暂。因此，联合用药方案提供了各种优势，包括增加成功率，减少副作用和减少耐药发生。姜黄素（Cur），一种来自姜黄植物的潜在植物化学物质，当与传统化疗药物结合使用时，在临床和临床前研究中已经被证实可以提高癌症治疗的有效性。Cur不仅通过多种机制对癌细胞产生凋亡性细胞死亡作用，而且还通过下调多药耐药（MDR）货物来减少标准化疗药物的抗药性。最近的报告显示了Cur与多种化疗药物联合治疗在各种恶性肿瘤中取得的有益结果。然而，由于生物利用度有限，在临床设置中需要设计Cur和传统药物的共输送策略。本综述总结了Cur与标准治疗的各种联合用药作为抗癌治疗的方法。

Standard cancer chemotherapeutics often produce significant adverse effects and eventually lose their effectiveness due to the emergence of resistance mechanisms. As a result, patients with malignant tumors experience a poor quality of life and a short lifespan. Thus, combination medication regimens provide various advantages, including increased success rate, fewer side effects, and fewer occurrences of resistance. Curcumin (Cur), a potential phytochemical from turmeric, when coupled with traditional chemotherapeutics, has been established to improve the effectiveness of cancer treatment in clinical and preclinical investigations. Cur not only exerts multiple mechanisms resulting in apoptotic cancer cell death but also reduces the resistance to standard chemotherapy drugs, mainly through downregulating the multi-drug resistance (MDR) cargoes. Recent reports showed the beneficial outcomes of Cur combination with many chemotherapeutics in various malignancies. Nevertheless, owing to the limited bioavailability, devising co-delivery strategies for Cur and conventional pharmaceuticals appears to be required for clinical settings. This review summarized various Cur combinations with standard treatments as cancer therapeutics.